Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Ionis Pharmaceuticals (NQ: IONS)
59.42 USD  -0.98 (-1.62%)
Official Closing Price  /  Updated: 5:01 PM EST, Jan 24, 2020  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 821,500
Open 60.53
Bid (Size) 59.00 (1)
Ask (Size) 63.00 (2)
Prev. Close 60.40
Today's Range 59.13 - 61.00
52wk Range 53.34 - 86.58
Shares Outstanding 125,520,380
Dividend Yield N/A
Performance
YTD
-2.41%
-2.41%
1 Month
-3.33%
-3.33%
3 Month
+7.14%
+7.14%
6 Month
-7.63%
-7.63%
1 Year
+1.16%
+1.16%
Top News
More News
Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx
Favorable safety and tolerability were demonstrated in hypertriglyceridemia patients in the study Read More
from PR Newswire
Technological Advancements Expand Biopharmaceuticals' Production Capabilities
FinancialBuzz.com News Commentary Read More
from PR Newswire
More News
Read More
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
from GlobeNewswire News Releases
Ionis appoints Onaiza Cadoret-Manier as chief corporate development and commercial officer
from PR Newswire
/C O R R E C T I O N -- Ionis Pharmaceuticals, Inc./
from PR Newswire
Ionis' neurological franchise marks year of achievement
from PR Newswire
Ionis Pharmaceuticals to present at 38th annual J.P. Morgan Healthcare Conference
from PR Newswire
New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
from GlobeNewswire News Releases
Ionis licenses investigational Alzheimer's therapy
from PR Newswire
Akcea Retains Rights to AKCEA-APOCIII-LRx
from GlobeNewswire News Releases
Ionis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
from PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.